CLVLF (CLVLF) Stock Price & Analysis
CLVLF (CLVLF) rose 0.00% to USD 6.4 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.
CLVLF last closed at USD 6.4; the session ranged USD 6.4–6.4 on volume of 3,000 shares. Market capitalization is $335.69M, with a 52-week range of USD 6.27–8.6 (PNK). Source: Nexqual, June 10, 2026 at 02:23 UTC.
Key Statistics (as of June 10, 2026 at 02:23 UTC)
| Price | USD 6.4 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 6.4 |
| Open | USD 6.4 |
| Day Range | USD 6.4 – 6.4 |
| 52-Week Range | USD 6.27 – 8.6 |
| Volume | 3,000 shares |
| Market Cap | $335.69M |
| Exchange | PNK |
Technical Analysis (CLVLF)
Nexqual's technical model rates CLVLF "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 02:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.16 (neutral) |
| vs SMA50 | Below (USD 6.92) |
| MACD | -0.14 (negative) |
Analyst Ratings (CLVLF)
Wall Street analysts rate CLVLF "None", per Nexqual as of June 10, 2026 at 02:23 UTC.
| Consensus Rating | None |
|---|
Earnings (CLVLF)
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financials & Fundamentals (CLVLF)
| Total Revenue | $96.30M |
|---|---|
| Revenue Growth (YoY) | +3.60% |
| Gross Margin | +89.63% |
| Operating Margin | +36.59% |
| Profit Margin | +33.79% |
| ROE | +13.96% |
| Debt / Equity | 0.13 |
| Current Ratio | 14.64 |
| Total Cash | $233.00M |
| Total Debt | $323,843 |
| Free Cash Flow | $32.20M |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financial Health Score (CLVLF)
Nexqual rates CLVLF's overall financial health "Strong" across five dimensions, as of June 10, 2026 at 02:23 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 90%, operating 37% |
| Balance Sheet | Strong — $233M cash, no debt |
| Cash Flow | Strong — FCF $32M, 34% margin |
| Efficiency | Mixed — ROE 14%, ROA 10.6% |
Ownership (CLVLF)
| Insider Ownership | +16.59% |
|---|---|
| Institutional Ownership | +8.58% |
| Shares Outstanding | 50.43M |
| Float | 41.57M |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Leadership (CLVLF)
CLVLF is led by Philippe Jacques Wolgen (age 62), CEO, MD & Director, per Nexqual as of June 10, 2026 at 02:23 UTC.
| CEO, MD & Director | Philippe Jacques Wolgen (age 62) |
|---|---|
| Chief Financial Officer | Peter Vaughan |
| Chief Scientific Officer | Dennis J. Wright BPharm, M.Sc. |
| Director of North American Operations | Linda Teng |
| Director of Global Clinical Affairs | Emilie Rodenburger |
Major Backers & Investors (CLVLF)
Notable institutional backers of CLVLF include DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series, Charles Schwab, according to Nexqual as of June 10, 2026 at 02:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series | 0.47% |
| Charles Schwab | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.39% |
| Dimensional Fund Advisors | 0.25% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLVLY | Clinuvel Pharmaceuticals Ltd. | USD 6.36 | ▼ 3.64% |
| MLLCF | Molecular Partners AG | USD 2.55 | ▼ 47.42% |
| OXBDF | Oxford Biomedica PLC | USD 8.44 | ▲ 6.63% |
| CMXHF | CSL Ltd. | USD 66 | ▼ 6.44% |
| INRLF | Valneva SE | USD 2.8 | ▲ 2.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.